Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review

Table 1 Patient and radioembolization characteristics of the original reports included in this review

Ref.	Number of patients with breast cancer	Mean age (yr)	Number of patients with extrahepatic disease	Type of microsphere used	Activity infused (GBq)
Bangash et al[16], 2007	27	52	N/A	Glass	2.05
Coldwell et al[17], 2007	44	58	29 (66%)	Resin	2.11
Stuart et al[18], 2008	7	N/A	1 (14%)	Resin	N/A
Jakobs et al[19], 2008	30	58	17 (57%)	Resin	1.9
Cianni et al[20], 2010	32	N/A	N/A	N/A	N/A
Haug et al[21], 2012	58	58	38 (65%)	Resin	1.8
Saxena et al[22], 2014	40	54.4	24 (60%)	Resin	1.67
Gordon et al[23], 2014	75	53.7	58 (77%)	Glass	1.52
Bagni et al[24], 2015	17	59.2	10 (59%)	Resin	N/A
Fendler et al[25], 2016	81	611	54 (67%)	N/A	1.61
Pieper et al[26], 2016	44	56.1	N/A	Resin = 56, Glass = 13	1.35
Chang et al[27], 2018	30	55*	5 (17%)	Resin = 46, Glass = 3	0.81

¹Median value as reported in the original report. N/A: Data not available.

Table 2 Tumour response to radio-embolization and survival data as reported in the studies included

Ref.	Evaluable patients	Assessment criteria	Follow up (mo)	Tumour response rate (%)	Cases of CR/PR/SD/PD	Overall survival (mo)
Bangash et al[16], 2007	23	WHO	N/A	21/23 (91%)	CR = 9 (39%); PR = 12 (52%); SD = 2 (9%); PD = 0	N/A
Coldwell et al[17], 2007	36	WHO	14	34/36 (94.4%)	CR = 0; PR = 17 (47.2%); SD = 17 (47%); PD=2 (6%)	> 14 for those with CR/PR, 3.6 for those with SD/PD
Stuart et al[18], 2008	7	N/A	N/A	N/A	N/A	20.91
Jakobs et al[19], 2008	23	RECIST	15.7	22/23 (97.2%)	CR = 0; PR = 14 (61%); SD = 8 (35%); PD = 1 (4%)	9.6
Cianni et al[20], 2010	32	RECIST	N/A	32/32 (100%)	CR = 14 (44%); PR = 11 (34%); SD = 7 (22%); PD = 0	N/A
Haug et al[21], 2012	43	RECIST	6	38/43 (88%)	CR = 0; PR = 11 (26%); SD = 27 (62%); PD = 5 (12%)	10.8
Saxena et al[22], 2014	38	RECIST	11.21	27/38 (71%)	CR = 2 (5%); PR = 10 (26%); SD = 15 (39%); PD = 11 (29%)	13.6
Gordon et al[23], 2014	25	RECIST	N/A	21/25 (84%)	CR = 3 (12%); PR/SD = 18 (72%); PD = 4 (16%)	6.61
Bagni et al[24], 2015	17	RECIST	N/A	17/17 (100%)	CR = 2 (12%); PR = 15 (88%); SD = 0; PD = 0	13.5
Fendler et al[25], 2016	56	N/A	N/A	29/56 (52%)	N/A	81
Pieper et al[26], 2016	38	RECIST	N/A	27/38 (71%)	CR = 0; PR = 11 (29%); SD = 16 (42%); PD = 11 (29%)	6
Chang et al[27], 2018	29	mRECIST	N/A	14/29 (48%)	CR = 0; PR = 12 (40%); SD = 2 (0.6%); PD = 15 (50%)	12.9

¹Median value as reported in the original study. N/A: Not available; WHO: World Health Organization; RECIST: Response Evaluation Criteria in Solid Tumours; mRECIST: Modified Response Evaluation Criteria in Solid Tumours; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.